Compare Boston Scientific Corporation (BSX) vs Williams Companies Inc (WMB) Price & Performance

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

WMB trades at $73.72, up 2.6% today, with a bullish technical signal and strong analyst support. The company reported mixed quarterly earnings but raised full-year EBITDA guidance to $8.4 billion following its $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast footprint. Fundamentals show robust profitability with a 25.18% net income margin and 24.02% ROE, though valuation multiples like a P/E of 28.81 appear elevated.

The outlook is positive, driven by growth initiatives and stable cash flows, but risks include execution of the large acquisition and sensitivity to energy demand. With a consensus price target of $87.14 implying 18% upside, the stock offers growth potential tempered by integration challenges and debt levels.